Memorial Sloan Kettering Cancer Center
Trastuzumab deruxtecan induces durable responses in HER2-mutated NSCLC
Trastuzumab deruxtecan demonstrated strong antitumor activity among patients with previously treated HER2-mutated non-small cell lung cancer, according to results of a multicenter phase 2 trial presented during the virtual ESMO Congress.
Nivolumab-ipilimumab combination confers durable benefit in advanced renal cell carcinoma
First-line nivolumab plus ipilimumab conferred durable survival benefit compared with sunitinib for patients with advanced renal cell carcinoma, according to results of the randomized phase 3 CheckMate-214 trial.
Immune Therapy and Surgical Interventions with Kevin C. Soares, MD
In this episode, Kevin C. Soares, MD, discusses his path to GI oncology, how immune therapy complements surgical interventions, and shares his thoughts on how the pandemic will impact medical practices.
Early-onset colorectal cancer may not be biologically different from average-onset disease
Early-onset colorectal cancer did not appear genomically distinct from average-onset disease, according to results of a retrospective, single-institution analysis published in Journal of the National Cancer Institute.
Some refractive errors may suggest retinoblastoma in infants
The University of Texas MD Anderson Cancer Center again ranked best cancer hospital in US
The University of Texas MD Anderson Cancer Center has retained its distinction as the No. 1 cancer hospital in the country.
Eliminating Cancer Health Disparities with Carol L. Brown, MD
In this episode, Carol L. Brown, MD, discusses her role as chief health equity officer at MSKCC, her thoughts on the future of structural inequities, strategies to diversify clinical trials, and more.
FDA grants regular approval to Keytruda-Lenvima combination for endometrial carcinoma
The FDA granted regular approval to the combination of pembrolizumab and lenvatinib for certain women with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient.
Germline testing may benefit all patients with metastatic, recurrent cancer, data suggest
Multigene germline genetic testing should be considered for all patients with advanced cancer to better guide treatment selection, according to study results published in Journal of Clinical Oncology.
Use of aggressive, costly end-of-life cancer treatment varies by race, insurance status
An analysis of patients with metastatic cancer revealed higher use of low-value, aggressive and more costly end-of-life interventions for those who belonged to racial or ethnic minority groups, according to retrospective study results.